Cyramza and Hyperkalaemia - a phase IV clinical study of FDA data

Summary:

Hyperkalaemia is reported as a side effect among people who take Cyramza (ramucirumab), especially for people who are male, 60+ old, have been taking the drug for 1 - 6 months also take Ondansetron, and have Hepatocellular carcinoma.

The phase IV clinical study analyzes which people have Hyperkalaemia when taking Cyramza. It is created by eHealthMe based on reports of 4,051 people who have side effects when taking Cyramza from the FDA, and is updated regularly.

What is Cyramza?

Cyramza has active ingredients of ramucirumab. eHealthMe is studying from 4,052 Cyramza users. Check the latest studies of Cyramza.

What is Hyperkalaemia?

Hyperkalaemia (damage to or disease of the kidney) is found to be associated with 2,845 drugs and 2,931 conditions by eHealthMe. Check the latest studies of Hyperkalaemia.

On Jun, 27, 2026

4,051 people reported to have side effects when taking Cyramza.
Among them, 9 people (0.22%) have Hyperkalaemia.

Among these 9 people:

How long have people been on Cyramza when they have Hyperkalaemia? *

What is the gender of people who have Hyperkalaemia when taking Cyramza? *

female: 25 %
male: 75 %

What is the age of people who have Hyperkalaemia when taking Cyramza? *

What are other drugs people take besides Cyramza? *

What are other side effects people have besides Hyperkalaemia? *

Malignant Neoplasm Progression (cancer tumour came back): 4 people, 44.44%
Peritonitis (inflammation of the peritoneum, the thin tissue that lines the inner wall of the abdomen and covers most of the abdominal organs): 2 people, 22.22%
Hyponatremia (abnormally low level of sodium in the blood; associated with dehydration): 2 people, 22.22%
Gastrointestinal Perforation (hole in the digestive tract): 2 people, 22.22%
Smell - Impaired: 1 person, 11.11%
Diarrhea: 1 person, 11.11%
Alanine Aminotransferase Increased: 1 person, 11.11%
Altered State Of Consciousness (altered state of mind): 1 person, 11.11%
Anaemia (lack of blood): 1 person, 11.11%
Appetite - Decreased (decreased appetite occurs when you have a reduced desire to eat): 1 person, 11.11%

What are the existing conditions these people have? *

Hepatocellular Carcinoma (liver cancer): 3 people, 33.33%
Hypoaesthesia (reduced sense of touch or sensation): 2 people, 22.22%
Gastric Cancer (stomach cancer): 2 people, 22.22%
Nausea (feeling of having an urge to vomit): 1 person, 11.11%
Metastases To The Mediastinum (cancer spreads to mediastinum): 1 person, 11.11%
Metastases To Lung (cancer spreads to lung): 1 person, 11.11%
Lung Cancer - Non-Small Cell (lung cancer): 1 person, 11.11%
Colon Cancer: 1 person, 11.11%
Cachexia (loss of weight): 1 person, 11.11%

* Approximation only. Some reports may have incomplete information.

Do you take Cyramza and have Hyperkalaemia?

- Check whether Hyperkalaemia is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Cyramza:

Cyramza (4,052 reports)

Hyperkalaemia treatments and more:

Hyperkalaemia (78,084 reports)

Browse all side effects of Cyramza:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Hyperkalaemia:

Hyperkalaemia (2,845 drugs)

Browse all the conditions that are associated with Hyperkalaemia:

Hyperkalaemia (2,931 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on ramucirumab (the active ingredients of Cyramza) and Cyramza (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.